Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mean Residence Time

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    78 result(s) found for: Mean Residence Time. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2017-002723-16 Sponsor Protocol Number: PREMIVER Start Date*: 2018-04-20
    Sponsor Name:Universitaetsklinikum Tuebingen
    Full Title: Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial
    Medical condition: In spite of remarkable progress over the last 15 years, malaria continues to be a major public health problem in the developing world with an estimated 214 million cases and 438.000 deaths in 2014....
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003866-14 Sponsor Protocol Number: B5091007 Start Date*: 2017-06-15
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older
    Medical condition: Primary C difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    20.0 10021881 - Infections and infestations 10012748 Diarrhoea, Clostridium difficile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) SE (Completed) HU (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) PT (Completed) ES (Completed) PL (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-005615-17 Sponsor Protocol Number: RPL554-008-2014 Start Date*: 2015-04-22
    Sponsor Name:Verona Pharma plc
    Full Title: A Phase II, randomised, double blind, placebo controlled, seven way crossover study to assess the effect of single doses of RPL554 compared to salbutamol and placebo administered by nebuliser on lu...
    Medical condition: Patients with chronic asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10049106 Asthma chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003306-40 Sponsor Protocol Number: E2006-G000-202 Start Date*: 2018-02-27
    Sponsor Name:Eisai Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhy...
    Medical condition: Irregular Sleep-Wake Rhythm Disorder in Subjects with Mild to Moderate Alzheimer’s Disease Dementia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000654-12 Sponsor Protocol Number: CE1145_1001 Start Date*: 2008-09-01
    Sponsor Name:Fachbereich Medizin der Johann Wolfgang Goethe-Universität Frankfurt/M.
    Full Title: PHARMACOKINETIC BERINERT P STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN SUBJECTS WITH MODERATE HEREDITARY ANGIOEDEMA - THE PASSION STUDY
    Medical condition: Patients with hereditary angioedema (HAE) suffer from recurring and mostly unforeseeable attacks of acute oedema of subcutaneous tisses of various organs. The pathophysiological correlate of this d...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003995-65 Sponsor Protocol Number: TAKICARD-1 Start Date*: 2015-11-25
    Sponsor Name:Västra Götalandsregionen, Sahlgrenska University Hospital /Queen Silvia children's hospital
    Full Title: Pharmacokinetics of ANP, a diuretic hormone, in neonates undergoing surgery for congenital heart defects. A pilot study.
    Medical condition: Acute renal failure after heart surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10038447 Renal failure neonatal PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001030-29 Sponsor Protocol Number: V212-014 Start Date*: 2014-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Double-blind, Lot-to-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults
    Medical condition: Prevention of herpes zoster in adults with autoimmune disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004343-23 Sponsor Protocol Number: IG0902 Start Date*: 2018-03-20
    Sponsor Name:INSTITUTO GRIFOLS, S.A.
    Full Title: Studio per indagare le proprietà farmacocinetiche (per vedere quanto è attivo il farmaco di studio nel sangue e quanto tempo ci vuole per il farmaco di studio per uscire dal sangue), l'efficacia e ...
    Medical condition: Congenital Afibrinogenemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10052651 Afibrinogenaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001442-34 Sponsor Protocol Number: IBUPAI0002 Start Date*: 2013-08-06
    Sponsor Name:McNeil AB
    Full Title: A SINGLE-DOSE, RANDOMIZED, TWO-PERIOD, CROSSOVER STUDY TO ASSESS BIOEQUIVALENCE BETWEEN TWO IBUPROFEN 200 MG TABLET FORMULATIONS, IN HEALTHY ADULTS.
    Medical condition: Pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004154-25 Sponsor Protocol Number: 984 Start Date*: 2013-06-25
    Sponsor Name:Biotest AG
    Full Title: A prospective, open-label, phase I/II study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenit...
    Medical condition: Patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016075 Factor I deficiency PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-000872-25 Sponsor Protocol Number: 106372 Start Date*: 2008-08-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals’ adjuvanted influenza candidate vaccine [GSK2186877A], administered intramusc...
    Medical condition: Immunization against influenza in male and female subjects aged 65 years or older.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) EE (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023003-96 Sponsor Protocol Number: BAY86-4875/91741 Start Date*: 2012-04-25
    Sponsor Name:Bayer HealthCare AG
    Full Title: Open-label, multicenter, pharmacokinetic, and safety study in children (term newborn infants to 23 months of age) undergoing a contrast-enhanced MRI with an intravenous injection of 0.1 mmol/kg BW ...
    Medical condition: Pediatric subjects aged <2 years (term newborn infants to toddlers 23 months of age inclusive) scheduled to undergo routine gadolinium-enhanced MRI of any body region
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004451-70 Sponsor Protocol Number: NOR-GRASPALL-2016 Start Date*: 2017-04-06
    Sponsor Name:Department of pediatrics, Aarhus University Hospital
    Full Title: NOR-GRASPALL 2016: SINGLE-ARM PHARMACOKINETIC/PHARMACODYNAMIC AND SAFETY STUDY OF ERYASPASE (GRASPA®) FOR PATIENTS WITH HYPERSENSITIVITY TO PEG-ASPARAGINASE, DIAGNOSED WITH PH(-) ACUTE LYMPHOBLASTI...
    Medical condition: Patients with acute lymphoblastic leukemia with allergy against PEG-asparaginase
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) NO (Completed) FI (Completed) SE (Completed) EE (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004128-42 Sponsor Protocol Number: E2609-G000-302 Start Date*: 2017-07-25
    Sponsor Name:Eisai Ltd.
    Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease
    Medical condition: Early Alzheimer Disease including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) PT (Prematurely Ended) FI (Prematurely Ended) HU (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004544-32 Sponsor Protocol Number: CT-P27/2.1 Start Date*: 2014-02-10
    Sponsor Name:Celltrion, Inc
    Full Title: Randomized, double-blind, placebo-controlled, single-centre, phase IIa study in healthy volunteers to evaluate the efficacy and safety of CT-P27 in an influenza challenge model
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002239-11 Sponsor Protocol Number: MYK-491-003 Start Date*: 2019-04-18
    Sponsor Name:MyoKardia Inc.
    Full Title: Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses...
    Medical condition: Heart Failure with Reduced Ejection Fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001477-33 Sponsor Protocol Number: 071102 Start Date*: 2016-12-01
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleed...
    Medical condition: Hereditary severe von Willebrand Disease in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Ongoing) IT (Ongoing) GB (GB - no longer in EU/EEA) BE (Ongoing) CZ (Completed) ES (Ongoing) FR (Ongoing) DE (Completed) NL (Ongoing) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2011-005679-18 Sponsor Protocol Number: GMX04 Start Date*: 2011-12-07
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
    Medical condition: Primary immunodeficiency diseases
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: Removed from public view
    EudraCT Number: 2018-003414-40 Sponsor Protocol Number: LTI-201 Start Date*: 2019-01-31
    Sponsor Name:Liquidia Technologies, Inc.
    Full Title: A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Response and Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1...
    Medical condition: Pulmonary Arterial Hypertension (WHO Group 1)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077739 Pulmonary arterial hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004307-40 Sponsor Protocol Number: ATN-106 Start Date*: 2022-01-31
    Sponsor Name:Octapharma AG
    Full Title: A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing sur...
    Medical condition: Congenital antithrombin deficiency
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004850 10083881 Antithrombin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) AT (Ongoing) FR (Ongoing) IT (Ongoing) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA